DRMANAC RADOJE T 4
4 · COMPLETE GENOMICS INC · Filed Oct 28, 2011
Insider Transaction Report
Form 4
DRMANAC RADOJE T
Chief Scientific Officer
Transactions
- Exercise/Conversion
Common Stock, $0.01 par value
2011-10-27$1.50/sh+50,000$75,000→ 80,000 total - Disposition to Issuer
Common Stock, $0.001 par value
2011-10-27$5.26/sh−10,000$52,609→ 108,666 total(indirect: By Trust) - Gift
Common Stock, $0.01 par value
2011-10-27−80,000→ 0 total - Gift
Common Stock, $0.01 par value
2011-10-27+80,000→ 188,666 total(indirect: By Trust) - Exercise/Conversion
Stock Option (right to buy)
2011-10-27−50,000→ 168,501 totalExercise: $1.50Exp: 2020-02-23→ Common Stock (50,000 underlying) - Exercise/Conversion
Common Stock, $0.01 par value
2011-10-27$1.50/sh+30,000$45,000→ 30,000 total - Exercise/Conversion
Stock Option (right to buy)
2011-10-27−30,000→ 36,666 totalExercise: $1.50Exp: 2019-12-27→ Common Stock (30,000 underlying)
Holdings
- 13,333(indirect: By Corporation)
Common Stock, $0.01 par value
Footnotes (4)
- [F1]The shares sold were pursuant to a Rule 10b5-1 plan dated March 17, 2011. The transaction was executed in multiple trades in prices ranging from $5.14 to $5.39 inclusive. The price reported in Column 4 above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
- [F2]These shares are held by the Drmanac Family Trust dated June 21, 2000, Radoje Drmanac, Trustee.
- [F3]These shares are held by Callida Genomics, Inc., a corporation wholly owned by the Reporting Person and his wife.
- [F4]The shares vest pursuant to the following schedule: The shares subject to the option vest in 48 successive, equal monthly installments measured from August 12, 2009, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.